Document Detail

Global epidemiology of invasive meningococcal disease.
Jump to Full Text
MedLine Citation:
PMID:  24016339     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis, pneumonia, and other manifestations. In countries with high endemic rates, the disease burden places an immense strain on the public health system. The worldwide epidemiology of invasive meningococcal disease (IMD) varies markedly by region and over time. This review summarizes the burden of IMD in different countries and identifies the highest-incidence countries where routine preventive programs against Neisseria meningitidis would be most beneficial in providing protection. Available epidemiological data from the past 20 years in World Health Organization and European Centre for Disease Prevention and Control collections and published articles are included in this review, as well as direct communications with leading experts in the field. Countries were grouped into high-, moderate-, and low-incidence countries. The majority of countries in the high-incidence group are found in the African meningitis belt; many moderate-incidence countries are found in the European and African regions, and Australia, while low-incidence countries include many from Europe and the Americas. Priority countries for vaccine intervention are high- and moderate-incidence countries where vaccine-preventable serogroups predominate. Epidemiological data on burden of IMD are needed in countries where this is not known, particularly in South- East Asia and Eastern Mediterranean regions, so evidence-based decisions about the use of meningococcal vaccines can be made.
Authors:
Rabab Z Jafri; Asad Ali; Nancy E Messonnier; Carol Tevi-Benissan; David Durrheim; Juhani Eskola; Florence Fermon; Keith P Klugman; Mary Ramsay; Samba Sow; Shao Zhujun; Zulfiqar A Bhutta; Jon Abramson
Related Documents :
24291539 - Vaccination benefits and cost-sharing policy for non-institutionalized adult medicaid e...
23564429 - Hpv knowledge, attitudes, and beliefs among northern plains american indian adolescents...
18809879 - Influence of hen age and molting treatments on shell egg exterior, interior, and conten...
23837379 - Brucellosis in pastoral and confined livestock: prevention and vaccination.
22995839 - Therapeutic vaccines: the ultimate personalized therapy?
23410259 - Large measles outbreak in geneva, switzerland, january to august 2011: descriptive epid...
24956179 - Vaccination against δ-retroviruses: the bovine leukemia virus paradigm.
17014889 - Methods for determining microcystins (peptide hepatotoxins) and microcystin-producing c...
1100539 - Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative phar...
Publication Detail:
Type:  Journal Article     Date:  2013-09-10
Journal Detail:
Title:  Population health metrics     Volume:  11     ISSN:  1478-7954     ISO Abbreviation:  Popul Health Metr     Publication Date:  2013  
Date Detail:
Created Date:  2013-11-15     Completed Date:  2013-11-15     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  101178411     Medline TA:  Popul Health Metr     Country:  England    
Other Details:
Languages:  eng     Pagination:  17     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Popul Health Metr
Journal ID (iso-abbrev): Popul Health Metr
ISSN: 1478-7954
Publisher: BioMed Central
Article Information
Download PDF
Copyright © 2013 Jafri et al.; licensee BioMed Central Ltd.
open-access:
Received Day: 27 Month: 9 Year: 2012
Accepted Day: 6 Month: 9 Year: 2013
collection publication date: Year: 2013
Electronic publication date: Day: 10 Month: 9 Year: 2013
Volume: 11First Page: 17 Last Page: 17
PubMed Id: 24016339
ID: 3848799
Publisher Id: 1478-7954-11-17
DOI: 10.1186/1478-7954-11-17

Global epidemiology of invasive meningococcal disease
Rabab Z Jafri1 Email: rubab_rzj@hotmail.com
Asad Ali1 Email: asad.ali@aku.edu
Nancy E Messonnier2 Email: nar5@cdc.gov
Carol Tevi-Benissan3 Email: tevibenissanc@who.int
David Durrheim45 Email: david.durrheim@hnehealth.nsw.gov.au
Juhani Eskola6 Email: juhani.eskola@thl.fi
Florence Fermon7 Email: florence.fermon@msf.org
Keith P Klugman89 Email: kklugma@emory.edu
Mary Ramsay10 Email: mary.ramsay@hpa.org.uk
Samba Sow1112 Email: ssow@medicine.umaryland.edu
Shao Zhujun13 Email: shaozhujun@icdc.cn
Zulfiqar A Bhutta1 Email: zulfiqar.bhutta@aku.edu
Jon Abramson14 Email: jabrams@wakehealth.edu
1Department of Pediatrics and Child Health, Division of Women and Child Health, Aga Khan University, Stadium Road, Karachi, Pakistan
2Centers for Disease Control and Prevention, Atlanta, GA, USA
3Immunisation, Vaccines and Biologicals, World Health Organisation, Geneva, Switzerland
4School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
5Health Protection, Hunter New England Area, Wallsend, Australia
6Finnish National Institute for Health and Welfare (THL), Helsinki, Finland
7International vaccination working group, Médécins Sans Frontières, Paris, France
8Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA
9Respiratory and Meningeal Pathogens Research Unit, University of Witwatersrand and Medical Research Council, Johannesburg, South Africa
10Immunisation Department at the Health Protection Agency, Centre for Infections in Colindale, London, UK
11Center for Vaccine Development, Ministry of Health, Bamako, Mali
12School of Medicine, University of Maryland, Baltimore, MD, USA
13Institute for Communicable Disease Control and Prevention, Beijing, People’s Republic of China
14Wake Forest School of Medicine, Winston-Salem, NC, USA

Introduction

Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis, pneumonia, and other localized infections. There are 12 serogroups, but the majority of invasive meningococcal infections are caused by organisms from the A, B, C, X, Y, or W-135 serogroups. The annual number of invasive disease cases worldwide is estimated to be at least 1.2 million, with 135,000 deaths related to invasive meningococcal disease (IMD) [1,2]. In countries with high endemicity, the disease burden places an immense strain on the public health system. The risk of long-term disabling sequelae, including cognitive deficit, bilateral hearing loss, motor deficit, seizures, visual impairment, hydrocephalus, and loss of limbs due to tissue necrosis, are highest in low-income countries, where the burden of bacterial meningitis is greatest [3].

To combat IMD, many industrialized countries have included different formulations of meningococcal vaccine in their routine immunization programs. A vaccine against serogroup A has recently been introduced in the African meningitis belt, an area extending from Senegal in the west to Ethiopia in the east [4,5]. However, meningococcal vaccines remain underutilized globally, particularly in resource-limited countries outside the African meningitis belt. To provide cost effective recommendations about the use of meningococcal vaccines, the country-specific burden of IMD must be established [6]. A comprehensive review of IMD incidence, including all countries with at least a basic surveillance infrastructure reporting IMD cases, was conducted. The review provides the most recently published attack rates, predominant serogroups, and at-risk groups from over 80 countries and organizes the data according to priority groups for vaccine intervention.


Methods
Search strategy and selection criteria

Our sources for the epidemiological data included the National Library of Medicine (PubMed), the World Health Organization (WHO) website of the Weekly Epidemiological Record, and the European Centre for Disease Prevention and Control. We searched PubMed with the following key terms: (“Neisseria meningitidis”) OR (“meningococcal”) OR (“meningococcemia”) OR (“meningococcus”). The search was limited to studies of humans, studies published in English, and dates of publication from January 1, 1990, to December 31, 2010. The initial search yielded 5,336 results from which studies were excluded based on exclusion criteria below. In addition, data were obtained and included from WHO publications in the Weekly Epidemiological Record (WER) for the latest figures from 14 African meningitis belt countries. The European Union Invasive Bacterial Infections Surveillance Network (EU-IBIS), which is maintained by the European Centre for Disease Prevention and Control, was accessed for updated figures for European countries and these data were also included. We searched reference lists in all identified articles for additional articles, and reviewed abstracts and titles and selected studies if it seemed they included aspects of meningococcal epidemiology. From the above literature search we excluded generic worldwide estimates (except to identify original data references), or studies that were limited to immunology, drug resistance, or other non-epidemiological factors.

Organization of data

The WHO definition of a meningococcal disease epidemic (>100 cases/100,000 population/year) applies specifically to the meningitis belt. Other countries rarely experience epidemics with these high attack rates. We classified countries according to the level of endemic meningococcal disease as “high,” “moderate,” and “low” endemicity (Figure 1). This classification is based on country-specific epidemiological data with pre-defined cutoffs of high, moderate, and low endemicity categories and was used by the WHO’s Strategic Advisory Group of Experts on Immunizations (SAGE) in its recently updated recommendations on the use of meningococcal vaccines [7].


Results
Epidemiology of meningococcal disease at country level

Data on incidence of meningococcal disease are presented below in Tables 1, 2 and 3. Countries are grouped into priority regions according to the definitions above, using national and published data from the last 20 years. Countries not listed in the table have insufficient available IMD epidemiological data to permit accurate classification.

Significant gaps in data limit description of IMD epidemiology in some parts of the world. In many countries with IMD surveillance, extensive targeted vaccine development and increasing coverage has decreased the burden of disease. In some endemic countries without vaccination, high IMD attack rates continue. The specific regional epidemiology is summarized in Figure 2 and described in terms of WHO regions below.

African region

The African Meningitis Belt, originally characterized by Lapeysonnie in 1963 [5] and modified in 1987, has the highest annual incidence of meningococcal disease in the world with superimposed frequent epidemics that constitute a major public health burden. Outbreaks in the sub-Saharan region coincide with the dry season, which has led to a hypothesis for the potential role of low humidity and seasonal dust-wind blowing from the Sahara (the Harmattan) in damaging the mucosa and producing irritant coughing that aids transmission [34,43].

Twenty-five countries in the African region with an extremely high incidence of meningococcal disease constitute the meningitis belt. To rapidly detect the frequent epidemics, a strong surveillance system exists that monitors the number of cases on an ongoing basis for rapid response. This region has recently benefitted from a major alliance of international health bodies that have developed and are deploying an affordable and effective vaccine against serogroup A meningococcus, which causes the majority of disease in this area, at population level [44].

Serogroup X, previously a rare cause of sporadic meningitis, has been responsible for outbreaks between 2006 and 2010 in Kenya, Niger, Togo, Uganda, and Burkina Faso, the latter with at least 1,300 cases of serogroup X meningitis among the 6,732 reported annual cases [45].

South Africa is included in the moderate-endemicity group, while other countries in this region do not have adequate data to enable derivation of a population-based estimate of their true incidence rates.

Eastern Mediterranean region

Sudan and Saudi Arabia have high endemic rates of serogroup A disease, and have also experienced outbreaks in recent years during the hajj season with serogroup W-135. Other countries in this region do not have adequate data to permit a population-based estimate of true incidence, although outbreaks have been reported among returning travelers from Hajj.

European region

With the exception of a few countries in the eastern part of the European Region, good surveillance data are available from most European countries. Serogroup B and C are responsible for the majority of disease, and implementation of a meningococcal immunization program with adequate vaccine coverage has contributed to decreasing endemic rates so that no country now falls in the high-endemicity group. Fifteen countries from this region are classified as moderate endemicity and 18 as low. Recent epidemiological surveillance indicates an increase of serogroup Y IMD in some parts of Europe, which is now the third most common serogroup after B and C [23].

Region of the Americas

Uruguay remains the only country from this region to have experienced high rates of IMD within the past 20 years. In 2001, it suffered a peak incidence rate of meningococcal disease due to serogroup B and this prompted the introduction of the Cuban outer membrane vesicle (OMV) B vaccine with good coverage and a sharp decline in incidence in subsequent years. Brazil and Cuba have experienced moderate incidence rates, but have also seen significant benefit from the introduction of meningococcal vaccines in their populations [29]. Argentina, Canada, Chile, Columbia, Mexico, the United States, and Venezuela have experienced low levels of IMD in the timeframe defined by this review. Serogroup Y emerged in Colombia and Venezuala, where it became the common disease-causing serogroup in 2006 [19]. The US has a universal meningococcal vaccine (conjugated quadrivalent vaccine given to adolescents) and Canada also recommends a booster dose in this age group following primary immunization at 12 months of age. Other countries in this region do not have adequate data to allow population-based estimates of their true incidence.

South-East Asia Region

Korea and Thailand are the only countries from this region with published population-based estimates, which demonstrate low endemic rates. India has experienced repeated serogroup A epidemics, the most recent in 2005, but data are mostly available only from large city centers [46]. Sporadic and incomplete data from India, Bangladesh, Indonesia, Nepal, and Pakistan preclude their classification, and no data are available from Sri Lanka [36].

Western Pacific

New Zealand and Mongolia have recorded high IMD endemicity. New Zealand experienced an outbreak of serogroup B disease until an aggressive campaign with the OMV vaccine was initiated in 2004 that has contributed in part to lowering the incidence. Mongolia experienced serogroup A epidemics in the early 1990s. Australia currently experiences predominantly serogroup B disease with moderate attack rates after the introduction of a serogroup C vaccine saw a marked decline in rates of disease due to the C serogroup. China, Japan, Korea, Philippines, Singapore, Taiwan, and Thailand all experience low levels of IMD. Other countries in this region do not have adequate population-based data to allow estimation of their true incidence rates.

Age-specific attack rates

In many countries with epidemiological data, particularly in Europe and North America, the age distribution of meningococcal disease demonstrates two peaks [6,47-49]. The highest incidence is in infants less than one year of age, and a secondary rise in incidence occurs in adolescents and young adults. In one study in the meningitis belt, the age-incidence did not plateau until the late 20s. Fifteen years of data from Niger show that children under the age of five were more affected during epidemics when compared to non-epidemic years [50]. However, some studies have suggested a shift toward older age groups during epidemics [51].

The widespread and rapid use of effective antibiotics has contributed to bringing down the case fatality rate of IMD to between 10 and 20 percent, but it is generally higher in developing countries where access to higher levels of care may be delayed [52]. Despite advances in resuscitative techniques, surgical intervention, and critical care, there is a persistent mortality in the early hours of septicemia due to the rapid progression of disease.


Conclusion

IMD is a serious illness that can be rapidly progressive with resulting significant morbidity and mortality, even with treatment. Vaccines are available for the majority of serogroups that cause disease and have proven effective in reducing the disease incidence in countries that have applied them at the population level. Maximizing the global impact of these vaccines requires having them made available in regions that have the highest disease incidence.

This review used available data to define the burden of meningococcal disease in different countries. Countries were classified based on the disease endemicity, and available data on the most prevalent serogroups were reviewed to permit evidence-based decisions on meningococcal vaccine use. These data helped inform SAGE’s new recommendations on the use of meningococcal vaccines. Limitations of the review include exclusion of studies that were not published in English and the absence of an indicator of the quality of surveillance used to derive incidence rates. It is crucial that timely surveillance utilizing new molecular epidemiology tools is implemented to obtain epidemiological data on burden of meningococcal disease in countries where these are not known. With the licensing of a new affordable conjugated vaccine against serogroup A (licensed in Africa) and, more recently, a multicomponent serogroup B vaccine in Europe (January 2013), functioning surveillance will be necessary to monitor the impact of these vaccines through direct immunity and herd protection and allow for optimization of vaccination schedules.


Competing interests

The authors declare that they have no significant competing interests.


Authors’ contributions

All authors have made active contributions in conceptualizing, drafting, and editing this manuscript. All authors read and approved the final manuscript.


Authors’ information

This manuscript describes the major findings of the meningococcal vaccine working group commissioned by the Strategic Advisory Group of Experts (SAGE) of the WHO.


References
Rouphael NG,Stephens DS,Neisseria meningitidis: biology, microbiology, and epidemiologyMethods Mol BiolYear: 20121112021993636
Epidemics of meningococcal disease. African meningitis belt, 2001Wkly Epidemiol RecYear: 200111282288
Edmond K,Clark A,Korczak VS,Sanderson C,Griffiths UK,Rudan I,Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysisLancet Infect DisYear: 20101131732820417414
Greenwood BM,Williams JD, Burnie JThe epidemiology of acute bacterial meningitis in tropical AfricaBacterial meningitisYear: 1987London: Academic Press6191
Lapeyssonnie L,[Cerebrospinal Meningitis in Africa]Bull World Health OrganYear: 196311111414259333
Harrison LH,Pelton SI,Wilder-Smith A,Holst J,Safadi MA,Vazquez JA,Taha MK,LaForce FM,von Gottberg A,Borrow R,Plotkin SA,The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal diseaseVaccineYear: 2011113363337121376800
Meningococcal Vaccines: WHO position paper, November 2011Weekly Epidemiological RecordYear: 201152154022128384
Gaspar M,Leite F,Brumana L,Felix B,Stella AA,Epidemiology of meningococcal meningitis in Angola, 1994–2000Epidemiol InfectYear: 20011142142411811874
Molesworth AM,Thomson MC,Connor SJ,Cresswell MP,Morse AP,Shears P,Hart CA,Cuevas LE,Where is the meningitis belt? Defining an area at risk of epidemic meningitis in AfricaTrans R Soc Trop Med HygYear: 20021124224912174770
Epidemics of Meningococcal Disease, African Meningitis Belt, 2001Wkly Epidemiol RecYear: 200111281288
Raghunathan PL,Jones JD,Tiendrebeogo SR,Sanou I,Sangare L,Kouanda S,Dabal M,Lingani C,Elie CM,Johnson S,et al. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002J Infect DisYear: 20061160761616453255
WHOMeningitis season 2007–2008: moderate levels of meningitis activityGlobal Alert and Response-Disease Outbreak NewsYear: 2008Geneva: Wold Health Organisation
2001 - Meningococcal disease in the African Meningitis Belt - Update 3Global Alert and Response-Disease Outbreak NewsYear: 2001Geneva: World Health Organisation
Meningococcal disease in the African Meningitis Belt, epidemic season 2006Global Alert and Response-Disease Outbreak NewsYear: 2006World Health Organisation
Expanded Program on Immunization (EPI)Wkly Epidemiol RecYear: 199711109116
Epidemic meningococcal disease--Kenya and Tanzania: recommendations for travelers, 1990MMWR Morb Mortal Wkly RepYear: 1990111314
Boisier P,Nicolas P,Djibo S,Taha MK,Jeanne I,Mainassara HB,Tenebray B,Kairo KK,Giorgini D,Chanteau S,Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in NigerClin Infect DisYear: 20071165766317278055
WHOMeningococcal disease in Saudi Arabia and the Netherlands - UpdateGlobal Alert and Response-Disease Outbreak NewsYear: 2000World Health Organisation
Safadi MA,Cintra OA,Epidemiology of meningococcal disease in Latin America: current situation and opportunities for preventionNeurol ResYear: 20101126327120406604
Baker MG,Martin DR,Kieft CE,Lennon D,A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000J Paediatr Child HealthYear: 200111S13S1911885731
Mendsaikhan J,Watt JP,Mansoor O,Suvdmaa N,Edmond K,Litt DJ,Nymadawa P,Baoping Y,Altantsetseg D,Slack M,Childhood bacterial meningitis in Ulaanbaatar, Mongolia, 2002–2004Clin Infect DisYear: 200911Suppl 2S141S14619191628
von Gottberg A,du Plessis M,Cohen C,Prentice E,Schrag S,de Gouveia L,Coulson G,de Jong G,Klugman K,Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South AfricaClin Infect DisYear: 20081137738618181736
Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data (Stockholm: European Centre for Disease Prevention and Control).Year: 2013
Trotter CL,Chandra M,Cano R,Larrauri A,Ramsay ME,Brehony C,Jolley KA,Maiden MC,Heuberger S,Frosch M,A surveillance network for meningococcal disease in EuropeFEMS Microbiol RevYear: 200711273617168995
Kafetzis DA,Stamboulidis KN,Tzanakaki G,Kourea Kremastinou J,Skevaki CL,Konstantopoulos A,Tsolia M,Meningococcal group C disease in Greece during 1993–2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatriciansClin Microbiol InfectYear: 20071155055217378929
Muscat M,Spiteri G,Calleja N,Haider J,Gray SJ,Melillo JM,Mamo J,Cuschieri P,Invasive meningococcal disease in Malta: an epidemiological overview, 1994–2007J Med MicrobiolYear: 2009111492149819589903
Iversen BG,Aavitsland P,Meningococcal disease in Norway 1992–1995. Epidemiology and fatalityScand J Infect DisYear: 1996112532598863356
Meningococcal Disease [http://ec.europa.eu/health/ph_information/dissemination/echi/docs/meningoccocal_en.pdf].
Dickinson FO,Perez AE,Bacterial meningitis in children and adolescents: an observational study based on the national surveillance systemBMC Infect DisYear: 20051110316288649
Guidelines for the early clinical and public health management of meningococcal disease in Australia. - Revised Edition 2007Year: 2007Communicable Diseases Network Australia: Commonwealth Department of Health and Ageing
Efron AM,Sorhouet C,Salcedo C,Abad R,Regueira M,Vazquez JA,W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in ArgentinaJ Clin MicrobiolYear: 2009111979198019357205
Whalen CM,Hockin JC,Ryan A,Ashton F,The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidisJAMAYear: 1995113903947823384
Bettinger JA,Scheifele DW,Le Saux N,Halperin SA,Vaudry W,Tsang R,The impact of childhood meningococcal serogroup C conjugate vaccine programs in CanadaPediatr Infect Dis JYear: 20091122022419209096
MacLennan J,Kafatos G,Neal K,Andrews N,Cameron JC,Roberts R,Evans MR,Cann K,Baxter DN,Maiden MC,Stuart JM,Social behavior and meningococcal carriage in British teenagersEmerg Infect DisYear: 20061195095716707051
Bae SM,Kang YH,Serological and genetic characterization of meningococcal isolates in KoreaJpn J Infect DisYear: 20081143443719050348
Vyse A,Wolter JM,Chen J,Ng T,Soriano-Gabarro M,Meningococcal disease in Asia: an under-recognized public health burdenEpidemiol InfectYear: 201111921492496
Hu X,Surveillance of epidemiological features for epidemic cerebrospinal meningitis in China during 1980sZhonghua Liu Xing Bing Xue Za ZhiYear: 1990113213242125858
Shao Z,Li W,Ren J,Liang X,Xu L,Diao B,Li M,Lu M,Ren H,Cui Z,et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, ChinaLancetYear: 20061141942316458767
Infectious Agents Surveillance Report. Meningococcal meningitis, 1999–2004, Japan http://idsc.nih.go.jp/iasr/26/300/tpc300.html. (Report IAS ed., vol. 26. pp. 33–34; 2005:33–34.
Weekly Infectious Disease Bulletin-Ministry of Health, Singapore http://www.moh.gov.sg/content/dam/moh_web/Statistics/Infectious_Diseases_Bulletin/2011/December/2011_week_49.pdf. 2011.
Wilder-Smith A,Goh KT,Barkham T,Paton NI,Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriersClin Infect DisYear: 20031167968312627350
Wang JL,Liu DP,Yen JJ,Yu CJ,Liu HC,Lin CY,Chang SC,Clinical features and outcome of sporadic serogroup W135 disease TaiwanBMC Infect DisYear: 200611716420709
Greenwood BM,Blakebrough IS,Bradley AK,Wali S,Whittle HC,Meningococcal disease and season in sub-Saharan AfricaLancetYear: 198411133913426145036
Bishai DM,Champion C,Steele ME,Thompson L,Product development partnerships hit their stride: lessons from developing a meningitis vaccine for AfricaHealth Aff (Millwood)Year: 2011111058106421653957
Xie O,Pollard AJ,Mueller JE,Norheim G,Emergence of serogroup X meningococcal disease in Africa: need for a vaccineVaccineYear: 2013112852286123623866
Sinclair D,Preziosi MP,Jacob John T,Greenwood B,The epidemiology of meningococcal disease in IndiaTrop Med Int HealthYear: 2010111421143521054695
Dell E,Bedford D,McMahon B,Nicholson A,Meningococcal disease--management of serogroup C clusters in a hyperendemic areaIr Med JYear: 200111166168169
Annual report of the Australian Meningococcal Surveillance Programme, 2009Commun Dis IntellYear: 201011291302
Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patientsPediatricsYear: 200511496505
Campagne G,Schuchat A,Djibo S,Ousseini A,Cisse L,Chippaux JP,Epidemiology of bacterial meningitis in Niamey, Niger, 1981–96Bull World Health OrganYear: 19991149950810427935
Peltola H,Kataja JM,Makela PH,Shift in the age-distribution of meningococcal disease as predictor of an epidemic?LancetYear: 1982115955976125738
Cartwright K,Noah N,Peltola H,Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6–8 October, 2000VaccineYear: 2001114347435611534497

Figures

[Figure ID: F1]
Figure 1 

A categorization of countries according to IMD attack rates.



[Figure ID: F2]
Figure 2 

Distribution of common and predominant meningococcal serogroups by region. Predominant strains are highlighted in bold text.



Tables
[TableWrap ID: T1] Table 1 

Countries with high endemic rates (>10 cases/100,000 population) and/or > =1 epidemic over the last 20 years


Country Year Incidence/100,000 population Predominant serogroup Source Comments
African Region
Angola
1994–2000
19–230
*
[8]
 
Benin
1980–1999
6–57
 
[9,10]
 
Burkina Faso
2004–2009
26–187
 
[11,12]
 
Burundi
1980–1999
158
 
[9]
 
Cameroon
1–224
 
[13]
 
Centrafique
2004–2009
3 3–19.4
 
[12]
 
Chad
9.6–15.9
 
[12]
 
Cote de Ivoire
1980–1999
0-6
 
[14]
Despite its relatively low attack rate, Cote de Ivoire is included in this table due to its location in the meningitis belt
Ethiopia
0–104
A
[9,10]
 
Gambia
4–165
 
[9,15]
 
Ghana
0–108
 
[9,15]
 
Guinea
0–17
 
[12]
 
Guinea Bissau
0–133
 
[9]
 
Kenya
1990
267
 
[16]
 
Mali
2004–2009
2.6–12.9
 
[12]
 
Mauritania
1980–1999
0–14
 
[9]
 
Namibia
4–165
 
[9]
 
Niger
2004–2009
7.8–90.7
 
[17]
 
Nigeria
0.7–52.6
 
[12]
 
RD Congo
7.3–23.7
 
[12]
 
Rwanda
1980–1999
0–28
 
[9]
 
Senegal
0–53
 
 
Incidence >50 in 1983
Tanzania
1980–1999
0–19
 
 
 
Togo
2004–2009
6–13.2
 
[12]
 
Uganda
1980–1999
0–18
 
[14]
 
Eastern Mediterranean Region
Sudan
2008
*
A
[12]
Despite lack of data Sudan is included in this table due to its location in the meningitis belt
Saudi Arabia
2000
 
A, W-135
[18]
225 cases in month after 2000 Hajj season. Data from Saudi Arabia mostly includes cases from the Hajj season.
European Region
No country in this region is in the high rate category
Region of the Americas
Uruguay
2001
30 (pre-vaccine)
B
[19]
Vaccine comprising serogroup C capsular polysaccharide and the outer membrane vesicles of serogroup B meningococcus was used
1.6 (post-vaccine)
South-East Asia Region
No country in this region is in the high rate category
Western Pacific Region
New Zealand
1991–2000
17.4 (pre-vaccine)
B
[20]
An OMV vaccine for Serogroup B was introduced in 2004
2.6 (post-vaccine)
Mongolia 1994–1995 80-90 A [21]  

* Data not available.


[TableWrap ID: T2] Table 2 

Countries with moderate endemic rates (2–10 cases/100,000 population per year)


Country Year Incidence/100,000 population Predominant serogroup Source Comments
African Region
 
 
 
 
 
South Africa
2000–2005
0.8–4
B in Western Cape
[22]
 
Eastern Mediterranean Region
No country in this region is in the moderate rate category
European Region
Belgium
1999–2010
2.9 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C was introduced in 2002
0.89 (post-vaccine)
Denmark
1999–2010
1.19–3.5
B
[23,24]
 
Greece
 
0.49–2.0
C
[23,24]
A conjugate vaccine for group C introduced in 2001 in pediatric population[25]
Ireland
 
14.3 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C was
 
 
2.19 (post-vaccine)
 
 
introduced in 2001
Iceland
 
7.6 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C was
 
 
0.6 (post-vaccine)
 
 
introduced in 2002
Lithuania
2004–2010
1.4–2.6
*
[23,24]
 
Luxemburg
1999–2010
0.2–5.68
*
[23,24]
 
Malta
1994–2007
0.8–8.9
B, C
[26]
2 peaks in 2000 and 2006
Netherland
1999–2010
3.6 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C was introduced in 2002
0.86 (post-vaccine)
Norway
1992–2010
0.8–4.6
B
[23,27]
 
Portugal
2000–2010
0.74–3.0
B, C
[23,28]
 
Spain
1999–2010
3.52 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C introduced in 2001
0.88 (post vaccine)
Switzerland
1999–2004
1.16–2.36
C
[24]
A conjugate vaccine for group C introduced in 2005
Turkey
1997–2005
0.3–2.2
*
[28]
 
United Kingdom
1999–2010
5.4 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C introduced in 1999
1.63 (post vaccine)
Region of the Americas
Brazil
1998–2006
1–4.5
B, now C
[19]
A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1990
Cuba
1998–2003
3.4-8.5 (pre-vaccine)
B
[29]
A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1987
<1 (post-vaccine)
South-East Asia Region
No country in this region is in the moderate rate category
Western Pacific Region
Australia 1995–2006 3.5–7.9 (pre-vaccine)
B [30] A conjugate vaccine for Serogroup C was introduced in 2003
1.4 (post-vaccine)

* Data not available.


[TableWrap ID: T3] Table 3 

Countries with low endemic rates (<2 case/100,000 population per year)


Country Year Incidence/100,000 population Predominant serogroup Source Comments
 
 
 
African Region
 
 
 
 
No country in this region is in the low rate category
 
 
 
 
European Region
 
 
Austria
1999–2010
1.02–1.2
B, C
[23,24]
 
Bulgaria
2000–2010
0.11–1.1
*
[23,28]
 
Croatia
1997–2005
0.7–1.3
*
[28]
 
Cyprus
1997–2010
0.13–1.7
*
[23,28]
 
Czech Republic
1999–2010
0.57–1.0
B, C
[23,24]
 
Estonia
2001–2010
0.15–1.6
*
[23,28]
 
Finland
1999–2010
0.64–1.1
B
[23,24]
 
France
0.7–1.13
B, C
 
Germany
0.47–0.73
B, C
 
Hungary
2004–2010
0.3–0.4
*
 
Italy
1999–2010
0.25–0.55
B, C
 
Latvia
2004–2008
0.25–1.03
*
 
Poland
1999–2010
0.17–0.84
B
 
Serbia
2000
0.9
*
[28]
 
Slovakia
2004–2010
0.59–0.9
*
[23,24][23,24]
 
Slovenia
1999–2010
0.3–1.2
*
 
Sweden
2004–2010
0.5–0.7
B, C
 
 
 
 
Eastern Mediterranean Region
 
 
 
 
No country in this region is in the low rate category
 
 
 
 
Region of the Americas
 
 
Argentina
2009
0.6
B
[31]
 
Canada
1985–2006
1.4 (pre-vaccine)
C
[32,33]
Vaccination in 2001–2 in all provinces
0.4 (post-vaccine)
Chile
1998–2006
0.8
B
[19]
 
Columbia
0.3
Y
 
Mexico
0.1
C
 
USA
2000–2009
0.8 (pre-vaccine)
Equal B, C,Y
[34]
Routine vaccination program started in 2005
0.3 (post-vaccine)
Venezuela
 
0.3
Y
[19]
 
 
 
 
South-East Asia Region
 
 
Korea
2002–2008
<0.1
 
[35]
 
Thailand
2007–2008
<0.1
 
[36]
Higher in <5 year olds
 
 
 
Western Pacific Region
 
 
China
2000 onward
<0.2
A, C
[37,38]
 
Japan
1999–2004
<0.02
*
[39]
 
Philippines
2004–2008
<0.1
A
[1]
 
Singapore
2005–2009
0.1–0.2
 
[36,40]
25/100,000 in Hajj pilgrims in 2000 [41]
Taiwan
2000–2001
0.1–0.2
A
[42]
 
 
 
Eastern Mediterranean Region
 
    No country in this region is in the low rate category  

*Data not available.



Article Categories:
  • Review

Keywords: Meningococcus, Neisseria meningitidis, Invasive meningococcal disease, Meningitis, Epidemiology, Meningitis belt.

Previous Document:  Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin...
Next Document:  Automatic Identification and Validation of Planar Collagen Organization in the Aorta Wall with Appli...